Alluvi, formerly BI 4744, offers a promising advance in weight loss therapy. This dual agonist targeting both GLP-1 and GIP sites demonstrates compelling efficacy in clinical studies, possibly outperforming existing https://alluvi-research.co.uk/product/tirzepatide-40mg-rd-only-alluvi/